Structural model of human PSA: A target for prostate cancer therapy

Chemical Biology and Drug Design

Volumn 70, Issue 3, 2007, Pages 261-267

  Hassan, Md Imtaiyaz ^a   Kumar, Vijay ^a   Singh, Tej P ^a   Yadav, Savita ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chymotrypsin; Homology modeling; Kallikrein; Prostate carcinoma; Three dimensional structure

Indexed keywords

AMINO ACID; ASPARTIC ACID; CHYMOTRYPSIN; HISTIDINE; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; SERINE; TRYPTOPHAN; TYROSINE;

ANTIGEN STRUCTURE; ARTICLE; BINDING SITE; CANCER THERAPY; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME SPECIFICITY; HYDROPHOBICITY; PRIORITY JOURNAL; PROSTATE CANCER;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATALYSIS; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; HUMANS; MALE; MERCURY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; ZINC;

EID: 34548182582     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00553.x     Document Type: Article

References (38)

1. Robert M., Gibbs B.F., Jacobson E., Gagnon C. (1997) Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36 : 3811 3819.
2. Yousef G.M., Diamandis E.P. (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22 : 184 204.
3. Watt K.W., Lee P.J., M'Timkulu T., Chan W.P., Loor R. (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 83 : 3166 3170.
4. Lilja H., Laurell C.B. (1985) The predominant protein in human seminal coagulate. Scand J Clin Lab Invest 45 : 635 641.
5. Yoshida E., Ohmura S., Sugiki M., Maruyama M., Mihara H. (1995) Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 63 : 863 865.
6. Diamandis E.P. (1995) New diagnostic applications and physiological functions of prostate specific antigen. Scand J Clin Lab Invest Suppl 221 : 105 112.
7. Hakalahti L., Vihko P., Henttu P., Autio-Harmainen H., Soini Y., Vihko R. (1993) Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 55 : 590 597.
8. Diamandis E.P. (1996) Prostate specific antigen - new applications in breast and other cancers. Anticancer Res 16 : 3983 3984.
9. Abrahamsson P.A., Lilja H., Falkmer S., Wadstrom L.B. (1988) Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12 : 39 46.
10. Narita D., Cimpean A.M., Anghel A., Raica M. (2006) Prostate-specific antigen value as a marker in breast cancer. Neoplasma 53 : 161 167.
11. Cheng C.W., Chan L.W., Ng C.F., Chan C.K., Tse M.K., Lai M.M. (2006) Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen. Int J Urol 13 : 463 465.
12. Diamandis E.P. (2000) Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem 46 : 896 900.
13. Cohen P., Peehl D.M., Graves H.C., Rosenfeld R.G. (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142 : 407 415.
14. Killian C.S., Corral D.A., Kawinski E., Constantine R.I. (1993) Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192 : 940 947.
15. Zhou A.M., Tewari P.C., Bluestein B.I., Caldwell G.W., Larsen F.L. (1993) Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39 : 2483 2491.
16. Diamandis E.P., Helle S.I., Yu H., Melegos D.N., Lundgren S., Lonning P.E. (1999) Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 85 : 891 898.
17. Petit J.H., Chen M.H., Loffredo M., Sussman B., Renshaw A.A., D'Amico A.V. (2006) Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 107 : 2180 2185.
18. Yang L., Zhang L.Y., Chen W.W., Kong F., Zhang P.J., Hu X.Y., Zhang J.Y., Cui F.A. (2005) Inhibition of the expression of prostate specific antigen by curcumin. Yao Xue Xue Bao 40 : 800 803.
19. Baumgart Y., Otto A., Schafer A., Usbeck E., Cott C., Schott A., Tornack M., Wenzel A., Mossie A., Birkenmeier G. (2005) Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to alpha 2-macroglobulin. Clin Chem 51 : 84 92.
20. Vihinen M. (1994) Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem Biophys Res Commun 204 : 1251 1256.
21. Villoutreix B.O., Getzoff E.D., Griffin J.H. (1994) A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 3 : 2033 2044.
22. Hagler A.T., Huler E., Lifson S. (1974) Energy functions for peptides and proteins: I. Derivation of a consistent force field including the hydrogen bond from amide crystals. J Am Chem Soc 96 : 5319 5327.
23. Krieger E., Darden T., Nabuurs S.B., Finkelstein A., Vriend G. (2004) Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57 : 678 683.
24. Mackay D.H.J. (1989) The Role of Energy Minimization Statistical Mechanics in Simulation Strategies of Biomolecular System. New York : Harper and Row/Plenum 26 p. 73 80.
25. Nielsen J.E., Vriend G. (2001) Optimizing the hydrogen-bond network in Poisson-Boltzmann equation-based pK(a) calculations. Proteins 43 : 403 412.
26. Gilson M.K., Honig B.H. (1988) Energetics of charge-charge interactions in proteins. Proteins 3 : 32 52.
27. Andrietti F., Peres A., Pezzotta R. (1976) Exact solution of the unidimensional Poisson-Boltzmann equation for a 1:2 (2:1) electrolyte. Biophys J 16 : 1121 1124.
28. Ramachandran G.N., Sasisekharan V. (1968) Conformation of polypeptides and proteins. Adv Protein Chem 23 : 283 438.
29. Gore S.P., Burke D.F., Blundell T.L. (2005) PROVAT: a tool for Voronoi tessellation analysis of protein structures and complexes. Bioinformatics 21 : 3316 3317.
30. Lovgren J., Tian S., Lundwall A., Karp M., Lilja H. (1999) Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 266 : 1050 1055.
31. Tanimoto H., Underwood L.J., Shigemasa K., Yan Yan M.S., Clarke J., Parmley T.H., O'Brien T.J. (1999) The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86 : 2074 2082.
32. Jones T.A., Thirup S. (1986) Using known substructures in protein model building and crystallography. EMBO J 5 : 819 822.
33. Blundell T.L., Cooper J., Foundling S.I., Jones D.M., Atrash B., Szelke M. (1987) On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry 26 : 5585 5590.
34. Bode W., Huber R. (1991) Proteinase-protein inhibitor interaction. Biomed Biochim Acta 50 : 437 446.
35. Lilja H., Cockett A.T., Abrahamsson P.A. (1992) Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 70 : 230 234.
36. Carvalho A.L., Sanz L., Barettino D., Romero A., Calvete J.J., Romao M.J. (2002) Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. J Mol Biol 322 : 325 337.
37. Fujinaga M., Sielecki A.R., Read R.J., Ardelt W., Laskowski M. Jr., James M.N. (1987) Crystal and molecular structures of the complex of alpha-chymotrypsin with its inhibitor turkey ovomucoid third domain at 1.8 A resolution. J Mol Biol 195 : 397 418.
38. Gourinath S., Degenhardt M., Eschenburg S., Moore K., Delucas L.J., Betzel C., Singh T.P. (2001) Mercury induced modifications in the stereochemistry of the active site through Cys-73 in a serine protease - crystal structure of the complex of a partially modified proteinase K with mercury at 1.8 A resolution. Indian J Biochem Biophys 38 : 298 302.